- Home
- RVTY vs MDGL Comparison
RVTY vs MDGL Comparison
Compare RVTY & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RVTY | MDGL |
|---|---|---|
| Founded | 1937 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 10.0B |
| IPO Year | 1994 | 2005 |
Fundamental Metrics
Financial Performance| Metric | RVTY | MDGL |
|---|---|---|
| Price | $92.36 | $432.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 14 |
| Target Price | $113.00 | ★ $637.92 |
| AVG Volume (30 Days) | ★ 1.2M | 351.9K |
| Earning Date | 04-27-2026 | 05-19-2026 |
| Dividend Yield | ★ 0.31% | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $3,311,822,000.00 | $180,133,000.00 |
| Revenue This Year | $6.34 | $58.70 |
| Revenue Next Year | $5.10 | $46.88 |
| P/E Ratio | $44.32 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $81.36 | $265.00 |
| 52 Week High | $119.02 | $615.00 |
Technical Indicators
Market Signals| Indicator | RVTY | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 36.93 | 38.33 |
| Support Level | $88.42 | $416.51 |
| Resistance Level | $95.99 | $452.22 |
| Average True Range (ATR) | 3.31 | 18.52 |
| MACD | -0.36 | 1.21 |
| Stochastic Oscillator | 27.11 | 20.01 |
Price Performance
Historical ComparisonAbout RVTY Revvity Inc.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.